Research
-
Uptake of Infliximab Biosimilars Among the Medicare Population
Two years after launch, biosimilars for rheumatoid arthritis and other lifelong conditions captured little market share.
Categorized in -
Lifetime Burden of Adult Congenital Heart Disease in the USA Using a Microsimulation Model
There is a significant burden of disease among individuals with CHD; the disease affects quality of life, disability, life expectancy, medical spending, chronic disease, as well as employment and education outcomes.
Categorized in -
The Value of Treatment for COVID-19
The COVID-19 pandemic has imposed significant and far-reaching health and economic costs. This white paper models and monetizes the health-related benefits of two hypothetical treatments administered either before or after hospitalization; both generate substantial value.
Categorized in -
Taking a Broader View of “Junk Insurance”
Christen Linke Young explains the dangers of junk insurance.
Categorized in -
The State of the Science in Opioid Policy Research
A review of 145 opioid policy evaluation studies found that greater adoption of more rigorous study designs and statistical methods is warranted.
-
Sex, Race, and Age Differences in Prevalence of Dementia in Medicare Claims and Survey Data
This study provides the first comparison of trends in dementia prevalence in the U.S. population using 3 different dementia ascertainments/data sources. They found there are still substantial differences across measures in dementia prevalence among Blacks and Hispanics.
-
The Economic Case for Public Investment in Stem Cell Research
Our analysis shows the measure resulted in over 56,000 jobs created and added approximately $10 billion to the state’s economy.
Categorized in -
State Approaches to Tackling the Opioid Crisis Through the Health Care System
States have implemented multiple strategies to enhance the capacity and quality of treatment services for opioid use disorder.
-
Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?
This study provides the first evidence to our knowledge that near‐universal access to Medicare at age 65 is associated with improvements in population‐level cancer mortality.
-
Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the U.S.
In a study published in Pharmacoeconomics, we find multiple blockbuster drugs have received exclusivity of more than 10 years through the Orphan Drug Act, thereby delaying access to generic/biosimilar equivalents.
Categorized in